C. Geoffrey Davis, Ph.D.
CEO and Chairman

Dr. Davis was a founder and the Chief Scientific Officer for Abgenix, Inc. in Fremont, California, where he led the development of the XenoMouse® technology, was involved in the research and development of Vectabix®, a fully human monoclonal antibody approved for colorectal cancer, and guided the discovery of 11 other antibodies currently in clinical trials. Abgenix was acquired by Amgen in early 2006. Prior to founding Abgenix, Dr. Davis was a faculty member at UCSF, an investigator with the Howard Hughes Medical Institute, and Director of Immunology at both Repligen Corp. and Cell Genesys, Inc. Dr. Davis received his Ph.D. in immunology from the University of California, San Francisco and completed his postdoctoral work at the University of Texas, Southwestern. He is the author of 37 publications and is an inventor on 12 issued patents.


Charles Bradley, Ph.D.

Vice President, Clinical Development

From 2005 to 2011, Dr. Bradley was Vice President, Clinical Development at BiPar Sciences, where he led clinical activities associated with development of BSI-201 (iniparib) in various types of solid tumors. Results of these efforts led to the acquisition of BiPar by Sanofi-Aventis. From 2000 to 2005, Dr. Bradley held a variety of positions with Amgen, both in the Medical Affairs and Clinical Development organizations. He had overall clinical operational responsibilities for programs across the oncology and nephrology therapeutic areas. Prior to joining Amgen, Dr. Bradley held senior positions in the clinical development group at Guilford Pharmaceuticals and in the Clinical Pharmacology department at Hoechst-Roussel Pharmaceuticals. Dr. Bradley also served as a pharmacokinetic reviewer for more than three years with the U.S. Food and Drug Administration. Dr. Bradley received his Ph.D. in Bioanalytical Chemistry from the University of Delaware, and obtained post-doctoral training in clinical pharmacology from the Uniformed Services University in Bethesda, Maryland. He also is a board-certified diplomate in Applied Pharmacology of the American Board of Clinical Pharmacology.


Jill Winter, Ph.D.

Director, Research

Dr. Winter has nearly 30 years of experience in research, including academia, big pharma, small biotech and nonprofit institutions. Her career as a molecular biologist has been focused on applying new technologies to age old problems such as antibiotic discovery, vaccine validation and discovery of therapeutic antibodies. She co-edited the first phage display workbook and is currently working on the second edition. Dr. Winter received her postdoctoral training at Monsanto in St Louis, MO, and her Ph.D. from the Department of Microbiology and Cell Science at the University of Florida, Gainesville.